There were bright spots in latest results from these two FTSE 100 companies, but the City is in no mood for any misses of which there were a few.
Both companies nudged up full-year revenues guidance but shares in the medical devices firm fell by 24.5p to 1,127p and the financial markets and data platform by 198p to 8,088p.
The stock exchange’s fall was driven by misses on costs and average subscription value (ASV) as its 4.1% rise in half-year earnings to £1.87 billion came in 2% short of City hopes.
Chief executive David Schwimmer called the performance “strong and broad-based” and said the business was well placed to deliver further growth in the second half and beyond.
He highlighted the performance in the largest division of Data & Analytics, where the company has focused on a deeper understanding of customers’ data strategies and day-to-day usage.
It has been rewarded through improved win rates and an increase in the average size of deals, recently including a multi-year partnership with Barclays.
- Daily Trading Flash: 10 most-traded shares 3 August 2023
- Rolls-Royce shares rally again as faith in new boss builds
- BP dividend increase is double expectations
The ASV growth within Data & Analytics was 6.9% at June, consolidating the significant improvements made over the last two years. However, LSE saw a small sequential decline in the second quarter due to short-term timing differences.
On the costs side, first-half operating expenses of £1.73 billion were 3% higher than expected although much of this miss came from a currency-related balance sheet adjustment.
As one of the market’s most crowded trades, UBS said the misses were bound to be viewed unfavourably even though they have been driven by one-off or temporary effects.
The bank has a price target of 9,800p, while Bank of America sits at 10,000p as it believes LSE is well placed to benefit from structural demand for data and analytics.
The company’s backers include fund manager Nick Train’s Finsbury Growth & Income (LSE:FGT) investment trust and Microsoft Corp (NASDAQ:MSFT) after the tech giant built a 4.2% stake as part of a strategic partnership.
Schwimmer reported strong early progress on the tie-up, with hundreds of people from both organisations focused on building and delivering the first products next year.
LSE now expects revenue growth towards the upper end of 6-8% guidance, similar to the message of Smith & Nephew after it forecast 6%-7% compared with 5%-6% previously.
This follows a first-half jump of 12% in the sports medicine and ear, nose and throat division, which provides products and instruments used to repair or remove soft tissue.
The advanced wound management and the knee and hip replacement divisions both achieved growth in the region of 6%.
- Interest rates rise to 5.25%: what does this mean for me?
- Investors like Taylor Wimpey's half-year results
- Next upgrades profit guidance yet again
Trading profit of $417 million (£328.9 million) fell from $440 million the year before, a figure that missed consensus by 6% after the margin contracted to 15.3% from 16.9%.
Smith & Nephew blamed one-off factors for the margin decline as it stuck by expectations for a full-year figure of at least 17.5%.
Chief executive Deepak Nath hopes to deliver a margin above 20% by 2025 as part of his 12-point plan to make Smith & Nephew a “consistently higher growth company”.
He reported the launch of 13 new products so far this year, with others planned in high growth segments such as robotics, shoulder replacement and negative pressure wound therapy.
UBS, which has a “sell” recommendation and price target of 1,040p, believes this year’s margin target now looks increasingly hard to achieve.
Even if the company reaches the bottom end of guidance, the bank said this implied just 20 basis points of margin expansion in a year of above normal revenue growth due to the one-off backlog recovery in elective procedures.
UBS said: “It still would need to deliver 125 basis points in 2024 and 2025 when we expect no such tailwind in order to meet management's above 20% target by 2025.”
These articles are provided for information purposes only. Occasionally, an opinion about whether to buy or sell a specific investment may be provided by third parties. The content is not intended to be a personal recommendation to buy or sell any financial instrument or product, or to adopt any investment strategy as it is not provided based on an assessment of your investing knowledge and experience, your financial situation or your investment objectives. The value of your investments, and the income derived from them, may go down as well as up. You may not get back all the money that you invest. The investments referred to in this article may not be suitable for all investors, and if in doubt, an investor should seek advice from a qualified investment adviser.
Full performance can be found on the company or index summary page on the interactive investor website. Simply click on the company's or index name highlighted in the article.